Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...
Stockhead on MSN
StockTake: First patient joins Tryptamine’s world-first IV psilocin trial for binge-eating disorder
Tryptamine Therapeutics have enrolled the first patient in its world-first intravenous psilocin trial for Binge Eating ...
A major Aussie university and ASX-listed company will deploy psychedelic drugs to treat binge-eating in a world-first clinical trial. Experimental healthcare company Tryptamine Therapeutics announced ...
Carhart-Harris, who is chair of TYP’s scientific advisory board, and Mediano, of the Imperial College London, will work with Tryptamine Therapeutics’ (ASX:TYP) to develop a proprietary EEG-based ...
Tryptamine Therapeutics has reached a milestone in development of its novel IV-infused psilocin formulation TRP-8803, with the drug meeting all phase 1b study objectives. Tryptamine Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback